ArticleBMC cancer2014
Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.European journal of nuclear medicine and molecular imaging · 2017Trial
- Article
- Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.Breast cancer research : BCR · 2025Article
- Development and validation of pan-cancer lesion segmentation AI-model for whole-body 18F-FDG PET/CT in diverse clinical cohorts.Computers in biology and medicine · 2025Article
- An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-bodyEJNMMI research · 2024Article
- Proposal to Improve the Image Quality of Short-Acquisition Time-Dedicated Breast Positron Emission Tomography Using the Pix2pix Generative Adversarial Network.Diagnostics (Basel, Switzerland) · 2022Article
- Effect of radioactivity outside the field of view on image quality of dedicated breast positron emission tomography: preliminary phantom and clinical studies.Annals of nuclear medicine · 2022Article
- Prognosis Associated with Glycolytic Activity in Regional Lymph Nodes of Patients with Previously Untreated Metastatic Breast Cancer: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2022Article
- Prognostic Value of Quantitative [Diagnostics (Basel, Switzerland) · 2021Article
- Evaluation of image quality at the detector's edge of dedicated breast positron emission tomography.EJNMMI physics · 2021Article
- Reduction of the fluorine-18-labeled fluorodeoxyglucose dose for clinically dedicated breast positron emission tomography.EJNMMI physics · 2019Article
- The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.Molecular imaging and biology · 2019Review
- Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients.EJNMMI research · 2016Article
- Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?European journal of nuclear medicine and molecular imaging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this retrospective study, the authors evaluated the prognostic value of whole-body total lesion glycolysis (WTLG) on FDG/PET images in metastatic breast cancer (MBC) patients.
methodsWe retrospectively evaluated 54 MBC patients who were diagnosed as having one or more metastatic lesions between June 2005 and March 2013. Twenty-four patients were diagnosed at the initial presentation (group A) and 30 patients were diagnosed for the first time at some point after a surgery (group B). Patients were excluded if they had received chemotherapy within 30 days before PET/CT. SUVmax and total TLG were calculated for all lesions in each patient and the highest SUVmax and the whole-body TLG (WTLG) values were used as independent variables for the analyses. Mean ages and the proportions of histopathological subtypes were compared between two groups using Mann-Whitney U test and Fisher's exact test, respectively. The prognostic significance of PET parameters was assessed using Cox proportional hazards regression analysis.
resultsFor groups A and B, the median follow-up period was 26 months (range, 3-58 months) and 40.5 months (range, 3-69 months), and the median age was 61 years (range, 42-81 years) and 59 years (range, 24-74 years), respectively. There were no significant differences between two groups in age (p = 0.294) or histopathological subtype (p = 0.384). In the univariate analyses, WTLG was found to be significantly associated with overall survival (OS) for patients of group A (p = 0.012). In the multivariate analysis, WTLG was also significantly associated with OS (p = 0.015). Only hormonal receptor level was a significant indicator of longer OS in patients with recurrent MBC (group B).
conclusionsThis study demonstrated that WTLG on PET/CT is an independent prognostic factor for survival in breast cancer patients with metastases at the initial presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.